Global Zoonotic Disease Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product Type;

Malaria, Tuberculosis, Relapsing fever, Viral Hepatitis, Rabies, and Others.

By Route of Administration;

Oral, Topical, and Others.

By Drug Class;

Antifungal, Antibacterial, Antibiotic, and Others.

By End User;

Hospitals, Specialty Clinics, Homecare, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn197339860 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Zoonotic Disease Treatment Market (USD Million), 2021 - 2031

In the year 2024, the Global Zoonotic Disease Treatment Market was valued at USD 47,192.98 million. The size of this market is expected to increase to USD 67,295.74 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.2%.

According to estimates from the Centers for Disease Control and Prevention, tens of thousands of Americans contract illnesses annually from diseases transmitted from animals to humans. This trend is expected to worsen with increased urbanization and rapid population growth, exacerbating the prevalence of zoonotic diseases. Poor sanitation rates in metropolitan areas contribute significantly to the spread of these diseases, driving demand for treatments. Additionally, the rising consumption of animal proteins is anticipated to lead to higher intake of animal fats, further fueling the market for zoonotic disease treatments.

Furthermore, the increasing number of households owning pets for entertainment and companionship poses another challenge, as some animals can carry dangerous diseases transmissible to humans. However, the lack of awareness about zoonotic diseases in impoverished nations and the high costs associated with research and development may hinder market expansion. Nonetheless, the global market is poised to benefit from the development of novel medications addressing specific animal healthcare needs in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product Type
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Drug Class

    4. Market Snapshot, By End User

    5. Market Snapshot, By Region
  4. Global Zoonotic Disease Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Zoonotic Diseases
        2. Growing Focus on R&D
      2. Restraints
        1. Drug Resistance
        2. High Cost of Treatment
      3. Opportunities
        1. Focus on Unmet Medical Needs
        2. Technological Advancements
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Zoonotic Disease Treatment Market, By Product Type, 2021 - 2031 (USD Million)
      1. Malaria
      2. Tuberculosis
      3. Relapsing fever
      4. Viral Hepatitis
      5. Rabies
      6. Others
    2. Global Zoonotic Disease Treatment Market, By Route of Administration , 2021 - 2031 (USD Million)
      1. Oral
      2. Topical
      3. Others
    3. Global Zoonotic Disease Treatment Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Antifungal
      2. Antibacterial
      3. Antibiotic
      4. Others
    4. Global Zoonotic Disease Treatment Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
    5. Global Zoonotic Disease Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Glaxo SmithKline
      2. Novartis
      3. Johnson & Johnson
      4. Pfizer, Inc
      5. Sanofi S.A
      6. F Hoffmann-La Roche Inc
      7. BioCryst Pharmaceuticals, Inc
      8. AstraZeneca
  7. Analyst Views
  8. Future Outlook of the Market